BioSpace9h
Merck’s Winrevair Cuts Morbidity, Mortality Risk by Over 75% in Phase III PAH Study
In high-risk patients with pulmonary arterial hypertension, Merck ’s fusion protein therapeutic Winrevair reduced the ...
FDA approves new drug to treat protein buildup in the heart
The FDA has approved a new drug for a serious heart condition that affects thousands of people. The drug, called Amvuttra ...
Technology Networks4d
CHO Cell Culture: The Engine of Biotherapeutic Production
This infographic highlights the key advantages of CHO cells and the technologies that are pushing the boundaries of cell ...
MPR1d
Sotatercept Reduces Major Events in High-Risk PAH Patients
Sotatercept-csrk reduced the risk of major morbidity and mortality events in adults with World Health Organization (WHO) Group 1 pulmonary arterial hypertension (PAH) functional class (FC) 3 or 4 at ...
Newly identified bacterial protein helps design cancer drug delivery system
A previously unknown protein in a family of bacteria found in soil and the human gut microbiome has been discovered—which ...
Taiwan News9d
Recombinant Chemicals Market Valued at USD 2.9 Billion in 2023, Projected to Grow at 7.8% CAGR Through 2032
The Global Recombinant Chemicals Market is valued at approximately USD 2.9 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 7.8% over the forecast period 2024-2032.
PipelineReview.com1d
Lynch Regenerative Medicine Acquires REGRANEX® Gel and Exclusive Rights to Use Recombinant Pure PDGF for Soft Tissue Rejuvenation and Regeneration
FRANKLIN, TN, USA I March 31, 2025 I Lynch Regenerative Medicine, LLC., (LRM) announced today that it has acquired exclusive rights to REGRANEX® gel and ...